Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide + LNG-IUD for Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight/Obese Women
NCT07349641Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Oct 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in endometrial atypical hyperplasia (AEH) and endometrial cancer (EC), sponsored by National Cancer Institute. Primary endpoint: Pathological Complete Response at 26 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
endometrial atypical hyperplasia (AEH)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07349641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349641.